tada...i was just spit balling, and using the 1.5 billion paid to Celator as a very rough yard stick.  I'm certain the $1.5 billion that Jazz Pharma paid, that it wasn't just for rights to the US patient population....so by comparing American patient populations with this form of Leukemia called AML, I think it made it more of an apples to apples comparison by using US patient populations for Diabets, CKD and the rest.  

If a fair comparison gives Apabetalone a value of let's say $10+ billion...just for arguments sake.  The question is simply, if DM has put a valuation of Apabetalone that's anywhere close to that figure, and who knows...maybe he pegs it much higher. Is that price tag too high for the likes of Pfizer or just about any other Pharma out there?  Pfizer's total market valuation in 2016 was around $155 billion USD...is Apabelaone worth 5% or more of their entire Market Cap?  I think it could be, and much more....but that's an awfully big bet.